RPCMC2 2019 - Risk & Pharmacovigilance MasterClass 2.0
Website https://glceurope.com/risk-and-pharmacovigilance-masterclass-2-details/?utm_source=ourglocal&utm_med |
Edit Freely
Category business; risk; management; medicine
Deadline: September 18, 2019 | Date: September 19, 2019-September 20, 2019
Venue/Country: Austria Trend Parkhotel Schönnbrunn Hietzinger Hau, Austria
Updated: 2019-08-09 18:14:31 (GMT+9)
Call For Papers - CFP
GLC Europe is excited to welcome you to the Risk & Pharmacovigilance MasterClass on the 19 - 20 September 2019 in the historical city of Vienna, Austria. The MasterClass will be led by Dimitris Zampatis, Associate director, Signal and Risk Management Process at Merck Biopharma, Germany.The focus of this two-day masterclass will be on providing an update of ongoing medicines' risk and signal management. Participants will also have the opportunity to get an insight on the current signal detection and management guidelines and tools. During this training, an outlook of current and future challenges in pharmacovigilance focusing on the impact of the General Data Protection Regulation (GDPR) in May 2018 will be given and discussed. By the end of this MasterClass, participants will:Learn all the details about the RMP Structure and compilationDiscover the risk minimization measuresHave a closer look on the signal detection and the MAH experience in EVDASGet to know the EU guidelines and the authorities’ expectation on signal managementFor the training description, detailed trainer profile and training program, please request the Training Agenda!Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.